Last Updated : May 1, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Vyxeos | daunorubicin and cytarabine | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vyzulta | latanoprostene bunod | Open-angle glaucoma or ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
| Wakix | pitolisant hydrochloride | Narcolepsy | Do not reimburse | Complete | ||
| Waymade-Trientine | trientine hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Wegovy | semaglutide | Weight management | Do not reimburse | Complete | ||
| Welireg | belzutifan | von Hippel-Lindau disease-associated tumours | Reimburse with clinical criteria and/or conditions | Complete | ||
| Winlevi | clascoterone | Acne vulgaris | Withdrawn | |||
| Xalkori | Crizotinib | ROS1-positive advanced non-small cell lung cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xalkori | Crizotinib | Advanced Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
| Xalkori | Crizotinib | Advanced or Metastatic Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 1, 2024